---
title: "TPG GP A, LLC Discloses Investment at Odyssey Therapeutics with 7.8% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286814682.md"
description: "TPG GP A, LLC disclosed a 7.8% stake in Odyssey Therapeutics, Inc. through a $25 million private placement. The investment allows TPG to influence Odyssey's strategy, although it currently has no plans for changes. TPG purchased 1,388,889 shares at $18 each and holds rights to register and resell its shares, with potential future actions including operational shifts or board changes to enhance shareholder value."
datetime: "2026-05-18T20:16:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286814682.md)
  - [en](https://longbridge.com/en/news/286814682.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286814682.md)
---

# TPG GP A, LLC Discloses Investment at Odyssey Therapeutics with 7.8% Stake

TPG GP A, LLC disclosed a 7.8% stake in Odyssey Therapeutics, Inc.’s common stock. The group bought shares through a $25 million concurrent private placement that closed on May 11, 2026, and filed its Schedule 13D on May 18, 2026. The investment grants registration rights and positions TPG to influence Odyssey’s strategy if it chooses.

**Investor Intent**

TPG LSI Rise Orazio II, L.P., an affiliate overseen by TPG GP A, purchased 1,388,889 shares at the IPO price of $18 per share under a Share Purchase Agreement. A separate Investors’ Rights Agreement gives TPG the right to register and resell its Odyssey shares.

TPG states it has no set plan to change Odyssey today, but it reserves the right to push for shifts in “operations, management or capital structure.” The filing also notes potential actions could include deals, asset sales, board changes, or further share purchases or sales “as a means of enhancing shareholder value.”

**Investor's Background**

TPG GP A, LLC is a Delaware limited liability company that acts as the ultimate general partner and managing member for TPG-affiliated investment vehicles. TPG is a global alternative asset firm known for private equity, growth, and impact investing across sectors including healthcare and technology. The firm has a long track record of active ownership and value creation in public and private companies.

Original SEC Filing: Odyssey Therapeutics, Inc. \[ ODTX \] - SCHEDULE 13D - May. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)
- [TPG.US](https://longbridge.com/en/quote/TPG.US.md)

## Related News & Research

- [Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake](https://longbridge.com/en/news/286603354.md)
- [Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake](https://longbridge.com/en/news/286825924.md)
- [These 3 engineering roles are now converging, says EY's AI leader](https://longbridge.com/en/news/286538922.md)
- [TPG Adds Admiral McRaven to Support Governance Shift](https://longbridge.com/en/news/282249006.md)
- [TPG Non-GAAP EPS of $0.26 misses by $0.34](https://longbridge.com/en/news/284939749.md)